Literature DB >> 19635911

TNFR1-dependent regulation of myeloid cell function in experimental autoimmune uveoretinitis.

Ben J E Raveney1, David A Copland, Andrew D Dick, Lindsay B Nicholson.   

Abstract

Experimental autoimmune uveoretinitis is an autoimmune disease induced in mice, which involves the infiltration of CD11b(+) macrophages and CD4(+) T cells into the normally immune-privileged retina. Damage is produced in the target organ following the activation of Th1 and Th17 T cells and by the release of cytotoxic mediators such as NO by activated macrophages. The majority of immune cells infiltrating into the retina are CD11b(+) myeloid cells, but, despite the presence of these APCs, relatively limited numbers of T cells are observed in the retina during the disease course. These T cells do not proliferate when leukocytes are isolated from the retina and restimulated in vitro, although they do produce both IFN-gamma and IL-17. T cell proliferation was restored by depleting the myeloid cells from the cultures and furthermore those isolated myeloid cells were able to regulate the proliferation of other T cells. The ability of macrophages to regulate proliferation depends on activation by T cell-produced IFN-gamma and autocrine TNF-alpha signaling in the myeloid cells via TNFR1. In the absence of TNFR1 signaling, relative T cell expansion in the retina is increased, indicating that regulatory myeloid cells may also act in vivo. However, TNFR1 signaling is also required for macrophages, but not T cells, to migrate into the target organ. Thus, in TNFR1 knock out mice, the amplification of autoimmunity is limited, leading to resistance to experimental autoimmune uveoretinitis induction.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19635911     DOI: 10.4049/jimmunol.0901340

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  28 in total

1.  The role of Gr1+ cells after anti-CD20 treatment in type 1 diabetes in nonobese diabetic mice.

Authors:  Changyun Hu; Wei Du; Xiaojun Zhang; F Susan Wong; Li Wen
Journal:  J Immunol       Date:  2011-12-02       Impact factor: 5.422

Review 2.  Interplay between innate and adaptive immunity in the development of non-infectious uveitis.

Authors:  François Willermain; James T Rosenbaum; Bahram Bodaghi; Holly L Rosenzweig; Sarah Childers; Travis Behrend; Gerhild Wildner; Andrew D Dick
Journal:  Prog Retin Eye Res       Date:  2011-11-22       Impact factor: 21.198

Review 3.  Doyne lecture 2016: intraocular health and the many faces of inflammation.

Authors:  A D Dick
Journal:  Eye (Lond)       Date:  2016-09-16       Impact factor: 3.775

Review 4.  MDSC in autoimmunity.

Authors:  James G Cripps; James D Gorham
Journal:  Int Immunopharmacol       Date:  2011-02-21       Impact factor: 4.932

5.  Tumour necrosis factor-mediated macrophage activation in the target organ is critical for clinical manifestation of uveitis.

Authors:  T K Khera; D A Copland; J Boldison; P J P Lait; D E Szymkowski; A D Dick; L B Nicholson
Journal:  Clin Exp Immunol       Date:  2012-05       Impact factor: 4.330

Review 6.  Cytokines in uveitis.

Authors:  Jessica E Weinstein; Kathryn L Pepple
Journal:  Curr Opin Ophthalmol       Date:  2018-05       Impact factor: 3.761

7.  The tumour necrosis factor/TNF receptor superfamily: therapeutic targets in autoimmune diseases.

Authors:  D S Vinay; B S Kwon
Journal:  Clin Exp Immunol       Date:  2011-03-14       Impact factor: 4.330

8.  Modelling experimental uveitis: barrier effects in autoimmune disease.

Authors:  David Nicholson; Emma C Kerr; Owen G Jepps; Lindsay B Nicholson
Journal:  Inflamm Res       Date:  2012-04-10       Impact factor: 4.575

9.  Systemic and local anti-C5 therapy reduces the disease severity in experimental autoimmune uveoretinitis.

Authors:  D A Copland; K Hussain; S Baalasubramanian; T R Hughes; B P Morgan; H Xu; A D Dick; L B Nicholson
Journal:  Clin Exp Immunol       Date:  2009-12-04       Impact factor: 4.330

Review 10.  Insights into the biology and therapeutic implications of TNF and regulatory T cells.

Authors:  Benoit L Salomon
Journal:  Nat Rev Rheumatol       Date:  2021-07-05       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.